Correlation of posaconazole minimum fungicidal concentration and time-kill test against nine Candida species

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 1004-1009

  Soczo G ^a   Kardos, G ^b   McNicholas, P M ^a   Balogh, E ^a   Gergely, L ^a   Varga, I ^c   Kelentey, B ^c   Majoros, L ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Antifungals; MFCs; Triazoles

Indexed keywords

POSACONAZOLE;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA INCONSPICUA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; FUNGICIDAL ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TORULOPSIDALES;

ANTIFUNGAL AGENTS; CANDIDA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; MICROBIAL SENSITIVITY TESTS; TIME FACTORS; TRIAZOLES;

EID: 35448944908     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm350     Document Type: Article

References (22)

1. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268-80.
2. Cantón E, Pemán J, Gobernado M et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004; 48: 2477-82.
3. Ernst EJ, Yodoi K, Roling EE et al. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 2002; 46: 578-81.
4. Girmenia C, Venditti M, Martino P. Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant Candide infections. Diagn Microbiol Infect Dis 2003; 46: 227-31.
5. Morace G, Polonelli L, for the GISIA group. Voriconazole activity against clinical yeast isolates: A multicentre Italian study. Int J Antimicrob Agent 2006; 26: 247-53.
6. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743872) and LY-303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
7. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole and amphotericin B against a large collection of clinically important moulds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
8. Chau AS, Chen G, McNicholas PM et al. Molecular basis for the enhanced activity of posaconazole against Absidia corymbifera and Rhizopus otyzae. Antimicrob Agents Chemother 2006; 50: 39117-9.
9. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
10. van Burik JH, Hare RS, Solomon HF et al. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006; 42: E61-5.
11. Espinel-Ingroff A, Fothergill A, Peter J et al. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204-8.
12. Perfect JR, Cox GM, Dodge RK et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910-3.
13. Barchiesi F, Arzeni D, Camiletti V et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001; 39: 4208-9.
14. Majoros L, Kardos G, Belak A et al. Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures. J Clin Microbiol 2003; 41: 5250-3.
15. Tavanti A, Davidson AD, Gow NAR et al. Candida orthopsilosis and Candida metapsilosis spp. nov., to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-92.
16. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Second Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002.
17. Sóczó G, Kardos G, McNicholas PM et al. Posaconazole susceptibility testing against Candida species: Comparison of broth microdilution and Etest methods. Mycoses 2007; 50: 178-82.
18. Klepser ME, Ernst EJ, Lewis RE et al. Influence of test conditions on antifungal time - kill curve results: Proposal for standardized methods. Antimicrob Agents Chemother 1998; 42: 1207-12.
19. Manavathu EK, Cutright JL, Loebenberg D et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-34.
20. de Wet N, Lianos-Cuentas A, Suleiman J et al. A randomized, double-blind, parallel-group, dose - response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-9.
21. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-5.
22. Skiest DJ, Vazquez JA, Anstead GM et al., Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44: 607-14.